Case Report: B-cell Acute Lymphoblastic Leukemia/Lymphoma Following Castleman Disease

² Experimental Teaching Center of Basic Medical Science, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, Jiangsu Province, China,

³ Jiangsu Provincial Second Chinese Medicine Hospital, The Second Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing, Nanjing 210000, Jiangsu Province, China,

⁴ Tiankang Hospital, Chuzhou 239300, Anhui Province, China,

⁵ Department of Neurology, Tianyou Hospital of Tongji University, Shanghai 200000, China,

OTD 2024 , 2(4), 21–34; https://doi.org/10.26689/otd.v2i4.9238

© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Castleman disease (CD) is a rare nonmalignant lymphoproliferative disorder presenting systemic symptoms such as fever, night sweats, fatigue, anemia, effusions, and multifocal lymphadenopathy. The etiology of CD has not been clarified to date. The coexistence of CD with B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL) has been rarely reported. Although the pathogenesis remains unclear, this association probably reflects an incidental and fortuitous finding rather than the alteration of a common pluripotent stem cell precursor. Herein, the study reports on one case of CD coexisting with B-ALL/LBL and elucidates the underlying mechanism of pathology in some aspects.

References

Castleman B, Iverson L, Menendez VP, 1956, Localized Mediastinal Lymph Node Hyperplasia Resembling Thymoma. Cancer, 9: 822–830.

Fajgenbaum DC, Uldriok TS, Bagg A, et al., 2017, International, Evidence-Based Consensus Diagnostic Criteria for HHV-8-Negative/Idiopathic Multicentric Castleman Disease. Blood, 129: 1646–1657.

Herrada J, Cabanillas F, Rice L, et al., 1998, The Clinical Behavior of Localized and Multicentric Castleman Disease. Annals of Internal Medicine, 128: 657–662.

Keller AR, Hochholzer L, Castleman B, 1972, Hyaline-Vascular and Plasma-Cell Types of Giant Lymph Node Hyperplasia of the Mediastinum and Other Locations. Cancer, 29: 670–683.

Rhee F, Voorhees P, Dispenzieri A, et al., 2018, International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease. Blood, 132: 2115–2124.

Wang HW, Pittaluga S, Jaffe ES, 2016, Multicentric Castleman Disease: Where Are We Now? Seminars in Diagnostic Pathology, 33: 294–306.

Kawabata H, Kadowaki N, Nishikori M, et al., 2013, Clinical Features and Treatment of Multicentric Castleman’s Disease: A Retrospective Study of 21 Japanese Patients at a Single Institute. Journal of Clinical and Experimental Hematopathology, 53: 69–77.

Fajgenbaum DC, Rhee F, Nabel CS, 2014, HHV-8-Negative, Idiopathic Multicentric Castleman Disease: Novel Insights into Biology, Pathogenesis, and Therapy. Blood, 123: 2924–2933.

Carbone A, Borok M, Damania B, et al., 2021, Castleman Disease. Nature Reviews Disease Primers, 7: 84.

Buitenkamp TD, Izraeli S, Zimmermann M, et al., 2014, Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Retrospective Analysis from the Ponte di Legno Study Group. Blood, 123: 70–77.

Faderl S, Jeha S, Kantarjian HM, 2003, The Biology and Therapy of Adult Acute Lymphoblastic Leukemia. Cancer, 98: 1337–1354.

Piktel D, Moore JC, Nesbit S, et al., 2023, Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia. Cancers (Basel), 15(3): 707.

Weisberg SP, Smith-Raska MR, Esquilin JM, et al., 2014, ZFX Controls Propagation and Prevents Differentiation of Acute T-Lymphoblastic and Myeloid Leukemia. Cell Reports, 6: 528–540.

Cobaleda C, Sanchez-Garcia I, 2009, B-Cell Acute Lymphoblastic Leukaemia: Towards Understanding Its Cellular Origin. Bioessays, 31: 600–609.

Rhee F, Stone K, Szmania S, et al., 2010, Castleman Disease in the 21st Century: An Update on Diagnosis, Assessment, and Therapy. Clinical Advances in Hematology & Oncology, 8: 486–498.

Terwilliger T, Abdul-Hay M, 2017, Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update. Blood Cancer Journal, 7: e577.

Muskardin TW, Peterson BA, Molitor JA, 2012, Castleman Disease and Associated Autoimmune Disease. Current Opinion in Rheumatology, 24: 76–83.

Tal Y, Haber G, Cohen MJ, et al., 2011, Autologous Stem Cell Transplantation in a Rare Multicentric Castleman Disease of the Plasma Cell Variant. International Journal of Hematology, 93: 677–680.

Yu L, Tu M, Cortes J, et al., 2017, Clinical and Pathological Characteristics of HIV- and HHV-8-Negative Castleman Disease. Blood, 129: 1658–1668.

Lee FC, Merchant SH, 2003, Alleviation of Systemic Manifestations of Multicentric Castleman’s Disease by Thalidomide. American Journal of Hematology, 73: 48–53.

Wolff H, Kunte C, Messer G, et al., 1999, Paraneoplastic Pemphigus with Fatal Pulmonary Involvement in a Woman with a Mesenteric Castleman Tumour. British Journal of Dermatology, 140: 313–316.

Jung CP, Emmerich B, Goebel FD, et al., 2004, Successful Treatment of a Patient with HIV-Associated Multicentric Castleman Disease (MCD) with Thalidomide. American Journal of Hematology, 75: 176–177.

Baecklund E, Smedby KE, Sutton LA, et al., 2014, Lymphoma Development in Patients with Autoimmune and Inflammatory Disorders—What Are the Driving Forces? Seminars in Cancer Biology, 24: 61–70.

Smedby KE, Vajdic CM, Falster M, et al., 2008, Autoimmune Disorders and Risk of Non-Hodgkin Lymphoma Subtypes: A Pooled Analysis Within the InterLymph Consortium. Blood, 111: 4029–4038.

Zhou T, Wang HW, Pittaluga S, et al., 2021, Multicentric Castleman Disease and the Evolution of the Concept. Pathologica, 113: 339–353.

Dispenzieri A, Fajgenbaum DC, 2020, Overview of Castleman Disease. Blood, 135: 1353–1364.

Mi JQ, Chen SJ, Zhou GB, et al., 2015, Synergistic Targeted Therapy for Acute Promyelocytic Leukaemia: A Model of Translational Research in Human Cancer. Journal of Internal Medicine, 278: 627–642.

Gordon S, Taylor PR, 2005, Monocyte and Macrophage Heterogeneity. Nature Reviews Immunology, 5: 953–964.

Mantovani A, Sica A, Locati M, 2005, Macrophage Polarization Comes of Age. Immunity, 23: 344–346.

Murray PJ, Wynn TA, 2011, Protective and Pathogenic Functions of Macrophage Subsets. Nature Reviews Immunology, 11: 723–737.

Biswas SK, Mantovani A, 2010, Macrophage Plasticity and Interaction with Lymphocyte Subsets: Cancer as a Paradigm. Nature Immunology, 11: 889–896.

Anderson CF, Mosser DM, 2002, Cutting Edge: Biasing Immune Responses by Directing Antigen to Macrophage Fc Gamma Receptors. Journal of Immunology, 168: 3697–3701.

Mosser DM, 2003, The Many Faces of Macrophage Activation. Journal of Leukocyte Biology, 73: 209–212.

Wynn TA, Chawla A, Pollard JW, 2013, Macrophage Biology in Development, Homeostasis and Disease. Nature, 496: 445–455.

Krausgruber T, Blazek K, Smallie T, et al., 2011, IRF5 Promotes Inflammatory Macrophage Polarization and TH1–TH17 Responses. Nature Immunology, 12: 231–238.

Sindrilaru A, Peters T, Wieschalka S, et al., 2011, An Unrestrained Proinflammatory M1 Macrophage Population Induced by Iron Impairs Wound Healing in Humans and Mice. Journal of Clinical Investigation, 121: 985–997.

Mariggio G, Koch S, Schulz TF, 2017, Kaposi Sarcoma Herpesvirus Pathogenesis. Philosophical Transactions of the Royal Society B: Biological Sciences, 372(1732): 20160275.

Burrer CM, Foight GW, Keating AE, et al., 2016, Selective Peptide Inhibitors of Antiapoptotic Cellular and Viral Bcl-2 Proteins Lead to Cytochrome C Release During Latent Kaposi’s Sarcoma-Associated Herpesvirus Infection. Virus Research, 211: 86–88.

Bhaskaran N, Ghosh SK, Yu X, et al., 2017, Kaposi’s Sarcoma-Associated Herpesvirus Infection Promotes Differentiation and Polarization of Monocytes into Tumor-Associated Macrophages. Cell Cycle, 16: 1611–1621.

Xu F, Cui WQ, Cui J, et al., 2018, Astragaloside IV Inhibits Lung Cancer Progression and Metastasis by Modulating Macrophage Polarization Through AMPK Signaling. Journal of Experimental and Clinical Cancer Research, 37: 207

Wang X, Luo G, Zhang K, et al., 2018, Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. Cancer Research, 78(4): 4586–4598.

Rahal OM, Wolfe AR, Mandal PK, et al., 2018, Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 100(4): 1034–1043.

Wu M, Zhang S, Chi C, et al., 2023, 1,5-AG Suppresses Pro-inflammatory Polarization of Macrophages and Promotes the Survival of B-ALL In Vitro by Upregulating CXCL14. Molecular Immunology, 158(1): 91–102.

Boutilier AJ, Elsawa SF, 2021, Macrophage Polarization States in the Tumor Microenvironment. International Journal of Molecular Sciences, 22(13): 6695.

Torisu H, Ono M, Kiryu H, et al., 2000, Macrophage Infiltration Correlates with Tumor Stage and Angiogenesis in Human Malignant Melanoma: Possible Involvement of TNFα and IL-1α. International Journal of Cancer, 85(2): 182–188.

Wang H, Yung MMH, Ngan HYS, et al., 2021, The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression. International Journal of Molecular Sciences, 22(12): 6560.

Bottini N, Firestein GS, 2013, Duality of Fibroblast-like Synoviocytes in RA: Passive Responders and Imprinted Aggressors. Nature Reviews Rheumatology, 9(1): 24–33.

Gasson JC, 1991, Molecular Physiology of Granulocyte-Macrophage Colony-Stimulating Factor. Blood, 77(1): 1131–1145.

Young DC, Griffin JD, 1986, Autocrine Secretion of GM-CSF in Acute Myeloblastic Leukemia. Blood, 68(1): 1178–1181.

Metcalf D, 1985, Molecular Control of Granulocyte and Macrophage Production. Progress in Clinical and Biological Research, 191(1): 323–337.

Weisbart RH, Golde DW, Clark SC, et al., 1985, Human Granulocyte-Macrophage Colony-Stimulating Factor is a Neutrophil Activator. Nature, 314(1): 361–363.

Yasunaga M, 2020, Antibody Therapeutics and Immunoregulation in Cancer and Autoimmune Disease. Seminars in Cancer Biology, 64(1): 1–12.

Ni X, Hu G, Cai X, 2019, The Success and the Challenge of All-Trans Retinoic Acid in the Treatment of Cancer. Critical Reviews in Food Science and Nutrition, 59(1): S71–S80.

Jansson C, Mengelbier LH, 2023, Retinoic Acid Promotes Differentiation of WiT49- but not of CCG99-11 Wilms Tumor Cells. Cancer Reports (Hoboken), 6(1): e1819.

Hung LF, Lai JH, Lin LC, et al., 2008, Retinoic Acid Inhibits IL-1-Induced iNOS, COX-2 and Chemokine Production in Human Chondrocytes. Immunological Investigations, 37(1): 675–693.

Zhang J, Deng B, Jiang X, et al., 2019, All-Trans-Retinoic Acid Suppresses Neointimal Hyperplasia and Inhibits Vascular Smooth Muscle Cell Proliferation and Migration via Activation of AMPK Signaling Pathway. Frontiers in Pharmacology, 10(1): 485.

Reynolds CP, Lemons RS, 2001, Retinoid Therapy of Childhood Cancer. Hematology/Oncology Clinics of North America, 15(1): 867–910.

He TR, Tang XY, Yan Q, et al., 2022, All-Trans Retinoic Acid-Incorporated Glycol Chitosan Nanoparticles Regulate Macrophage Polarization in Pg-LPS-Induced Inflammation. Current Medical Science, 42(1): 974–980.

Shimizu T, Esaki L, Mizuno H, et al., 2006, Granulocyte Macrophage Colony-Stimulating Factor Enhances Retinoic Acid-Induced Gene Expression. Journal of Leukocyte Biology, 80(1): 889–896.

Horie M, Broxmeyer HE, 1995, The Combination of Steel Factor and GM-CSF Blocks Apoptosis Induced by Retinoic Acid and Upregulates AP-1 in a Human Growth Factor-Dependent Cell Line. Experimental Hematology, 23(1): 168–173.

Shephard MT, Merkhan MM, Forsyth NR, 2022, Human Mesenchymal Stem Cell Secretome Driven T Cell Immunomodulation Is IL-10 Dependent. International Journal of Molecular Sciences, 23: 13596.

Moncivais OJR, Chavez SA, Jimenez VHE, et al., 2023, Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies. International Journal of Molecular Sciences, 24(19): 14573.

Dehghan R, Parikhani AB, Cohan RA, et al., 2024, Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of Its In Vitro Antitumor Activity. Current Pharmaceutical Design, 30(11): 868–876.

Gong T, Huang X, Wang Z, et al., 2024, IL-2 Promotes Expansion and Intratumoral Accumulation of Tumor Infiltrating Dendritic Cells in Pancreatic Cancer. Cancer Immunology, Immunotherapy, 73(5): 84.

Chen F, Gong M, Weng D, et al., 2024, Phellinus linteus Activates Treg Cells via FAK to Promote M2 Macrophage Polarization in Hepatocellular Carcinoma. Cancer Immunology, Immunotherapy, 73(1): 18.

Zhou H, Jiang B, Qian Y, et al., 2024, The Mechanistic Target of Rapamycin Complex 1 Pathway Contributes to the Anti-Tumor Effect of Granulocyte-Macrophage-Colony-Stimulating Factor-Producing T Helper Cells in Mouse Colorectal Cancer. Immunological Investigations, 53: 261–280.

Shin DS, Ratnapriya S, Cashin CN, et al., 2023, Lung Injury Induces a Polarized Immune Response by Self-Antigen-Specific CD4+ Foxp3+ Regulatory T Cells. Cell Reports, 42(8): 112839.

Leon B, 2023, A Model of Th2 Differentiation Based on Polarizing Cytokine Repression. Trends in Immunology, 44: 399–407.

Moynihan KD, Kumar MP, Sultan H, et al., 2024, IL-2 Targeted to CD8+ T Cells Promotes Robust Effector T Cell Responses and Potent Antitumor Immunity. Cancer Discovery, 14(7): 1206–1225.

Previous article in this issue

Next article in this issue